Acknowledgements
Cancer
CANCER
We acknowledge O. Jaen (Beckman Coulter) for the help with flow cytometry panel design. We thank the GenomEast platform, a member of the ‘France Génomique’ consortium (ANR-10-INBS- 0009) for scRNA-seq and RNA-seq. We also thank the Cytometry platform (IGBMC, Strasbourg) for the sorting experiments related to scRNA-seq. We thank E. Rederstorff for the operating organization of the study. The facility is supported by the Burgundy Regional Council. We would also like to thank S. Chevrier from the molecular biology laboratory of the Georges-François Leclerc Cancer Center for her involvement in the whole-exome sequencing and RNA-seq experiments. We also thank the biomonitoring platform of UMR 1098 for their technical support. This work was also possible thanks to the help of S. Monier and N. Pernet, from the Flow Cytometry Core Facility/INSERM LNC-UMR1231, at the University of Burgundy, for bioplex experiments. We also want to give thanks to all the members of the Plateforme de Cytométrie et d’Imagerie de Masse (IRCM, Montpellier) for the mass cytometry experiment. We acknowledge F. Ecarnot for helping with the preparation of the paper and correction of the English. We acknowledge the members of the independent safety monitoring committee (R. Abbas, B. Chauffert, J. Edeline and M. Hebbard). This study was supported by grants from AstraZeneca and from Georges-François Leclerc Cancer Center. None of the funders had any role in the study design, data collection, data analysis, data interpretation or writing of the report. AstraZeneca reviewed the first version of this paper.